ROLE OF HIGH DENSITY LIPOPROTEINS AGAINST PROSTATE CANCER
type: CreativeWork
description: Background. Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Although androgen deprivation therapy (ADT) is initially effective, many patients progress to castration-resistant disease with poor prognosis and limited treatment options, highlighting the need for new therapeutic strategies. The tumor microenvironment (TME) contains pro-oxidant, pro-inflammatory mediators and lipids such as cholesterol and fatty acids, which sustain proliferation, survival, and angiogenesis. Cholesterol can also be converted into oxysterols, endogenous LXR ligands that generally exert antiproliferative effects. However, 27-hydroxycholesterol (27-HC) has been shown to promote tumor growth in breast cancer, although its role in PCa remains controversial. Several studies report an inverse correlation between HDL-cholesterol levels and cancer prognosis, including in PCa. Beyond their atheroprotective role, HDL promote cholesterol efflux and exert anti-inflammatory, antioxidant, and immunomodulatory effects. Synthetic HDL (sHDL), currently under clinical evaluation as anti-atherosclerotic agents, retains these activities and can serve as drug delivery vehicles by targeting tumors through scavenger receptor BI (SR-BI), that is overexpressed in different tumor types, including PCa. Aim. Previous in vitro and in vivo studies have shown that HDL can inhibit PCa tumour growth by reducing intracellular cholesterol content and oxidative stress, inflammation and angiogenesis. However, the overall effects of HDL on cholesterol metabolism and their anti-inflammatory activities, especially in the context of the TME, should be deeply investigated. Thus, this study aims to characterize the effect of plasma-derived and sHDL on PCa proliferation and metabolism, focusing on oxysterols, and to better characterize the anti-inflammatory activities of HDL in the context of TME. Methods. Androgen-sensitive and -resistant PCa cell lines (LNCaP and PC-3, respectively) were tested a…
abstract: Background. Prostate cancer (PCa) is the second leading cause of cancer-related death in men. Although androgen deprivation therapy (ADT) is initially effective, many patients progress to castration-resistant disease with poor prognosis and limited treatment options, highlighting the need for new therapeutic strategies. The tumor microenvironment (TME) contains pro-oxidant, pro-inflammatory mediators and lipids such as cholesterol and fatty acids, which sustain proliferation, survival, and angiogenesis. Cholesterol can also be converted into oxysterols, endogenous LXR ligands that generally exert antiproliferative effects. However, 27-hydroxycholesterol (27-HC) has been shown to promote tumor growth in breast cancer, although its role in PCa remains controversial. Several studies report an inverse correlation between HDL-cholesterol levels and cancer prognosis, including in PCa. Beyond their atheroprotective role, HDL promote cholesterol efflux and exert anti-inflammatory, antioxidant, and immunomodulatory effects. Synthetic HDL (sHDL), currently under clinical evaluation as anti-atherosclerotic agents, retains these activities and can serve as drug delivery vehicles by targeting tumors through scavenger receptor BI (SR-BI), that is overexpressed in different tumor types, including PCa. Aim. Previous in vitro and in vivo studies have shown that HDL can inhibit PCa tumour growth by reducing intracellular cholesterol content and oxidative stress, inflammation and angiogenesis. However, the overall effects of HDL on cholesterol metabolism and their anti-inflammatory activities, especially in the context of the TME, should be deeply investigated. Thus, this study aims to characterize the effect of plasma-derived and sHDL on PCa proliferation and metabolism, focusing on oxysterols, and to better characterize the anti-inflammatory activities of HDL in the context of TME. Methods. Androgen-sensitive and -resistant PCa cell lines (LNCaP and PC-3, respectively) were tested a…
author: CETTI, FEDERICA
language: eng
keywords: Settore BIOS-11/A - Farmacologia
date published: 2025-12-15
date modified: 2026-07-27T20:18:46Z
provider: Università degli Studi di Milano
publisher: Networked Digital Library of Theses and Dissertations
type: WebPage
source organization: Università degli Studi di Milano

PropertyValue
property ID: Handle
value: https://hdl.handle.net/2434/1197296